Nanotherapeutics relieve rheumatoid arthritis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
• Current RA treatments face challenges like high drug dosage, frequent administration, and organ toxicity.
• Nanotherapeutic agents offer improved drug delivery and targeted accumulation in affected tissues.

Purpose of the Study:

• To review current anti-rheumatic drugs and nanotherapeutic strategies for RA.
• To illustrate the application of passive and active targeting nanotheranostics in RA treatment.
• To discuss the future potential of nanovehicles in clinical RA therapy.

Main Methods:

• Literature review of anti-RA agents and nanotherapeutic approaches.
• Systematic illustration of passive and active targeting nanotheranostics.
• Discussion and prediction of nanovehicle applications in RA.

Main Results:

• Nanotherapeutic agents can avert non-specific binding and enhance drug accumulation in RA lesions.
• Targeted nanotheranostics show potential for improved RA treatment efficacy.
• Nanovehicles offer a promising alternative to conventional RA therapies.

Conclusions:

• Nanotherapeutics represent a significant advancement in managing rheumatoid arthritis.
• Targeted nanotheranostics provide a strategy to overcome limitations of existing RA treatments.
• Nanovehicles hold considerable promise for future clinical applications in RA therapy.